Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

Members of the European Parliament, researchers, patient advocates, national experts, and representatives from the biotech ...

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against other ...

From decoy DNA sequences to plasmapheresis, researchers are testing strategies to get around anti-AAV antibodies that hinder ...

"The newer medications that are coming out, and a lot of them are approved, are much more focused on the problem," explains ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Ahead Therapeutics SL has received positive feedback from the EMA on its way toward initiating regulatory toxicology studies for its lead program in myasthenia gravis. The feedback supports the ...